Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial

BACKGROUND: Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist spironolactone can improve exercise capacity, E...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Heart Assoc
Autors principals: Shantsila, Eduard, Shahid, Farhan, Sun, Yongzhong, Deeks, Jonathan, Calvert, Melanie, Fisher, James P., Kirchhof, Paulus, Gill, Paramjit S., Lip, Gregory Y. H.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726985/
https://ncbi.nlm.nih.gov/pubmed/32909497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.016239
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars